Trial Profile

Study of PIP-101

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PIP 101 (Primary)
Indications Leukaemia
Focus Therapeutic Use

Most Recent Events

08 Apr 2024 According to a Shorla Oncology Media Release, announced today that the Agency assigned a Prescription Drug User Fee Act (PDUFA) action date of November 30, 2024.
11 Jul 2023 New trial record
06 Jul 2023 According to a Shorla Oncology Media Release, once Shorla has obtained approval of its New Drug Application (NDA), the company will be responsible for the timely launch, commercialization and sales of PIP-101 in the U.S..

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com